ALS Research Group

Umeå University Hospital

The ALS research group at Umeå University Hospital performs clinical studies, including phase 1—3 trials as well as molecular pathology research using genetic (DNA), proteomic (proteins) and metabolomic approaches.

UmeaUniversity_Logo
Umeå University Hospital

In 1992, the ALS Clinical Center was established at Umeå University Hospital. This is now the principal center for diagnosing and caring of patients with neuromuscular diseases in northern Sweden. The clinical team also performs second-opinion evaluations of patients from other parts of Sweden and from abroad. Since 1992 the center has conducted clinical phase 1—3 trials which concern investigator initiated clinical trials as well as studies with the industry. The ALS Clinical Center is part of the larger ALS Research Consortium in Umeå that also performs genetic, histopathology and molecular-pathology studies. The focus is on studying SOD1 and its role as a prion in causing cell death.

Contact
Location
Umeå University, Postadress:, Umeå, Sweden

Our Specialists

Peter Andersen

Professor of Neurology and Senior Neurologist

Professor Andersen obtained his medical degree from Copenhagen University and specialised in […]

Peter Andersen
Current trials
Recruiting
Phase ii

AP101-02

Industry trial
In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics (how a drug is absorbed and excreted) of AP-101 in patients with familial and sporadic amyotrophic lateral sclerosis (ALS). Currently, we are only looking for patients with familial ALS (caused by a SOD1 gene mutation) to participate in the study. This study is sponsored by AL-S Pharma.
Read more
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more